Document is current
Any future updates will be listed below
-
Authors
Stege, Claudia A. M. https://orcid.org/0000-0001-7476-0609
Nasserinejad, Kazem
Klein, Saskia K.
Timmers, Gert-Jan
Hoogendoorn, Mels
Ypma, Paula F.
Nijhof, Inger S.
Velders, Gerjo A. https://orcid.org/0000-0002-7475-9402
Strobbe, Leonie
Durdu-Rayman, Nazik
Westerman, Matthijs
Davidis-van Schoonhoven, Marjan A.
van Kampen, Roel J. W.
Beeker, Aart
Koster, Ad
Dijk, Amanda C.
van de Donk, Niels W. C. J.
van der Spek, Ellen
Leys, Rineke B. L.
Silbermann, Matthijs H.
Groen, Kaz
van der Burg-de Graauw, Nicole C. H. P.
Sinnige, Harm A. M.
van der Hem, Klaas G.
Levenga, Henriette
Bilgin, Yavuz M.
Sonneveld, Pieter
Levin, Mark-David https://orcid.org/0000-0003-2139-3547
Zweegman, Sonja
-
Funding
Funding for this research was provided by:
Janssen Pharmaceuticals
KWF Kankerbestrijding
- License Information
-
More Information
Article History
Received: 22 September 2020
Revised: 12 January 2021
Accepted: 26 January 2021
First Online: 15 February 2021
Compliance with ethical standards
:
: NvdD has received research support from Janssen, Amgen, Celgene, Novartis, and BMS; and serves in advisory boards for Janssen, Amgen, Celgene, BMS, Takeda, Roche, Novartis, Bayer, and Servier. ISN serves in advisory boards for and received speakers fee from Celgene and Takeda. PS has received research support from and serves in advisory boards for Janssen, Takeda, Skyline Dx, Karyopharm and Amgen. MDL has received travel support from Janssen, Takeda and Roche, and serves in advisory boards for Takeda. SZ has received research funding from and has served in advisory boards for Celgene, Janssen and Takeda, Sanofi and Oncopeptids. Other authors have no conflicts of interest to report.
